LifeMD, Inc. (LFMD)

In November 2025, LifeMD divested its stake in WorkSimpli Software and reported positive Q3 results. In March 2026, LifeMD reported strong Q4 and full-year 2025 results, launched oral Wegovy, and received an upgraded outlook from Mizuho. In April 2026, LifeMD announced it was offering Eli Lilly's Foundayo™ for weight management. In May 2026, LifeMD reported positive Q1 2026 results with a surge in active subscribers. A securities class action lawsuit was filed in August 2025 alleging misrepresentation of its competitive position, following a significant stock price drop after Q2 2025 results missed estimates.

LifeMD's telehealth services may experience some demand seasonality, although chronic condition management suggests relatively stable demand. Historical stock price data indicates higher probability of positive returns in May and March, and the lowest in December. Factors such as new year's resolutions or holiday spending patterns could contribute to these trends.

LifeMD, Inc. is a direct-to-patient telehealth company providing virtual healthcare services and pharmacy solutions across the United States, operating within the Health Information Services industry. Its business model combines virtual medical treatment with prescription medications and over-the-counter products, connecting patients in all 50 U.S. states with licensed healthcare providers for over 200 conditions. Key areas of focus include weight management, men's and women's health, dermatology, hormone therapy, and primary care. Major brands include RexMD for men's telehealth, ShapiroMD for hair loss, LifeMD PC for primary care, Nava MD for female dermatology, Cleared for allergy and asthma, and weight management programs offering GLP-1 medications.

LifeMD, Inc. operates its virtual healthcare services and pharmacy fulfillment across all 50 states in the United States.

LifeMD's brand reputation has been influenced by positive analyst ratings and high patient satisfaction, but also by a securities class action lawsuit filed in August 2025. The lawsuit alleged false statements regarding its competitive position and 2025 guidance, particularly concerning customer acquisition costs and refund rates, which negatively affected public perception.

LifeMD, Inc. has a mix of institutional, insider, and public ownership. As of May 8, 2026, 109 institutional owners held 18,590,482 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Renaissance Technologies Llc. Key individual owners include CEO Justin Schreiber, who held 2,703,715 shares as of June 2025, and co-founder Stefan Galluppi.